Cargando…
Substrate utilisation of cultured skeletal muscle cells in patients with CFS
Chronic fatigue syndrome (CFS) patients often suffer from severe muscle pain and an inability to exercise due to muscle fatigue. It has previously been shown that CFS skeletal muscle cells have lower levels of ATP and have AMP-activated protein kinase dysfunction. This study outlines experiments loo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588462/ https://www.ncbi.nlm.nih.gov/pubmed/33106563 http://dx.doi.org/10.1038/s41598-020-75406-w |
_version_ | 1783600377431588864 |
---|---|
author | Tomas, Cara Elson, Joanna L. Newton, Julia L. Walker, Mark |
author_facet | Tomas, Cara Elson, Joanna L. Newton, Julia L. Walker, Mark |
author_sort | Tomas, Cara |
collection | PubMed |
description | Chronic fatigue syndrome (CFS) patients often suffer from severe muscle pain and an inability to exercise due to muscle fatigue. It has previously been shown that CFS skeletal muscle cells have lower levels of ATP and have AMP-activated protein kinase dysfunction. This study outlines experiments looking at the utilisation of different substrates by skeletal muscle cells from CFS patients (n = 9) and healthy controls (n = 11) using extracellular flux analysis. Results show that CFS skeletal muscle cells are unable to utilise glucose to the same extent as healthy control cells. CFS skeletal muscle cells were shown to oxidise galactose and fatty acids normally, indicating that the bioenergetic dysfunction lies upstream of the TCA cycle. The dysfunction in glucose oxidation is similar to what has previously been shown in blood cells from CFS patients. The consistency of cellular bioenergetic dysfunction in different cell types supports the hypothesis that CFS is a systemic disease. The retention of bioenergetic defects in cultured cells indicates that there is a genetic or epigenetic component to the disease. This is the first study to use cells derived from skeletal muscle biopsies in CFS patients and healthy controls to look at cellular bioenergetic function in whole cells. |
format | Online Article Text |
id | pubmed-7588462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-75884622020-10-27 Substrate utilisation of cultured skeletal muscle cells in patients with CFS Tomas, Cara Elson, Joanna L. Newton, Julia L. Walker, Mark Sci Rep Article Chronic fatigue syndrome (CFS) patients often suffer from severe muscle pain and an inability to exercise due to muscle fatigue. It has previously been shown that CFS skeletal muscle cells have lower levels of ATP and have AMP-activated protein kinase dysfunction. This study outlines experiments looking at the utilisation of different substrates by skeletal muscle cells from CFS patients (n = 9) and healthy controls (n = 11) using extracellular flux analysis. Results show that CFS skeletal muscle cells are unable to utilise glucose to the same extent as healthy control cells. CFS skeletal muscle cells were shown to oxidise galactose and fatty acids normally, indicating that the bioenergetic dysfunction lies upstream of the TCA cycle. The dysfunction in glucose oxidation is similar to what has previously been shown in blood cells from CFS patients. The consistency of cellular bioenergetic dysfunction in different cell types supports the hypothesis that CFS is a systemic disease. The retention of bioenergetic defects in cultured cells indicates that there is a genetic or epigenetic component to the disease. This is the first study to use cells derived from skeletal muscle biopsies in CFS patients and healthy controls to look at cellular bioenergetic function in whole cells. Nature Publishing Group UK 2020-10-26 /pmc/articles/PMC7588462/ /pubmed/33106563 http://dx.doi.org/10.1038/s41598-020-75406-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Tomas, Cara Elson, Joanna L. Newton, Julia L. Walker, Mark Substrate utilisation of cultured skeletal muscle cells in patients with CFS |
title | Substrate utilisation of cultured skeletal muscle cells in patients with CFS |
title_full | Substrate utilisation of cultured skeletal muscle cells in patients with CFS |
title_fullStr | Substrate utilisation of cultured skeletal muscle cells in patients with CFS |
title_full_unstemmed | Substrate utilisation of cultured skeletal muscle cells in patients with CFS |
title_short | Substrate utilisation of cultured skeletal muscle cells in patients with CFS |
title_sort | substrate utilisation of cultured skeletal muscle cells in patients with cfs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588462/ https://www.ncbi.nlm.nih.gov/pubmed/33106563 http://dx.doi.org/10.1038/s41598-020-75406-w |
work_keys_str_mv | AT tomascara substrateutilisationofculturedskeletalmusclecellsinpatientswithcfs AT elsonjoannal substrateutilisationofculturedskeletalmusclecellsinpatientswithcfs AT newtonjulial substrateutilisationofculturedskeletalmusclecellsinpatientswithcfs AT walkermark substrateutilisationofculturedskeletalmusclecellsinpatientswithcfs |